Oncology

Excerpt from the Article: One of the most common cancers among men in the United States, prostate cancer is second in prevalence only to skin cancer. Approximately 12.5 percent of men will be diagnosed with prostate cancer at some point during their lifetimes. Put another way, out of every 100 American men, approximately 13 will get prostate cancer during…

Excerpt from the Press Release: BOSTON, July 15, 2021 /PRNewswire/ — COTA, Inc., an oncology real-world data and analytics company, announced a new research partnership with MedStar Health. COTA will support MedStar Health in its use of real-world data to accelerate scientific discovery and improve care for cancer patients. MedStar Health is the largest healthcare provider in the Maryland and Washington, D.C.,…

Excerpt from the Article: In men who have prostate cancer, pairing active surveillance with prostate MRI is a more cost-effective approach to treatment over time than relying on active surveillance, repeated biopsy and prostate-specific antigen (PSA) tests. These findings, published July 14 in Radiology, come on the heels of additional research that indicates prostate MRI can…

Excerpt from the Article: There is new evidence-based guidance for the use of low-dose CT (LDCT) for lung cancer screening from the American College of Chest Physicians. In an article published July 13 in CHEST, an expert panel from the College released 16 clinical recommendations based on a review of 75 studies. The new guidelines focus on…

Excerpt from the Press Release: MONMOUTH JUNCTION, N.J., July 15, 2021 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the initiation of its Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer. The study, being conducted at…

Excerpt from the Press Release: CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Denice Torres will join the company’s board of directors. Ms. Torres has over 25 years of executive leadership experience in healthcare across the consumer, biopharmaceutical…

Excerpt from the Press Release: SAN MATEO, Calif., July 8, 2021 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical) announced that data from a phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma (rHNSCC) was accepted for publication in the International Journal of Clinical Oncology and published on June 24, 2021.…

Excerpt from the Press Release: CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first acute myeloid leukemia (AML) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system,…